Lung Cancer News

• Immunotherapy Combos: Will Cost Put Them out of Reach? Immunotherapy has already revolutionized cancer care. Combining various immunotherapies promises even greater success, but will the already high cost of these therapies put combos out of reach?
  Medscape Medical News, October 2018
• Bristol-Myers' Opdivo Fails to Meet Lung Cancer Study Goal Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo (nivolumab) failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.
  Reuters Health Information, October 2018
• ATA 2018New RET Inhibitors Show Reduced Toxicities in Thyroid Cancer The precision-targeted therapies show early, encouraging signs of reduced toxicities for medullary, thyroid cancers.
  Medscape Medical News, October 2018
• Should Breast Surgery Be Its Own Medical Specialty? In the US, there are medical specialty boards for thoracic surgery, orthopedic surgery, head and neck surgery, colorectal surgery, and surgery for a variety of other organs/systems. But not the breast.
  Medscape Medical News, October 2018
• ALK Testing Rates Increasing in NSCLC Patients Testing for mutations in the ALK gene in patients with non-small-cell lung cancer (NSCLC) who are candidates for targeted therapy nearly doubled from 2011 to 2016, according to a new study in U.S. community practices.
  Reuters Health Information, October 2018
• ESMO 2018'Revolutionary' Data to Be Presented at ESMO 2018 Evolutions and even revolutions are expected when the latest data in head and neck cancer, renal cell carcinoma, breast cancer, and ovarian cancer are presented at the leading European cancer meeting.
  Medscape Medical News, October 2018
• Burden of Lung Cancer to Decrease Over Next 50 Years Thanks to tobacco control efforts implemented in the 1960s, the burden of lung cancer in the US will decrease, with deaths reduced by 79% over the next 50 years.
  Medscape Medical News, October 2018
• Anticoagulation Suboptimal in Patients With Cancer and AFib Patients seen by a cardiology provider had better outcomes but experts caution that randomized data have yet to catch up on the best care for this growing population of patients.
  Medscape Medical News, October 2018
• Cancer Trends in India: First Comprehensive Report The first comprehensive estimates for 28 cancers in each Indian state over 26 years (1990 - 2016) are now available, and they highlight prevailing disparities.
  Medscape Medical News, October 2018
• QCS 2018Cancer Care Comparable for Medicaid vs Commercial Insurance Cancer patients enrolled in Medicaid received care that was comparable or even superior to that of patients covered by commercial insurance.
  Medscape Medical News, October 2018
• WCLC 2018Survival Reduced in Lung Cancer Patients Who Refuse Surgery Lung cancer patients who refuse surgery face greatly compromised odds of overall survival compared to those who accept surgical resection.
  Medscape Medical News, October 2018
• WCLC 2018'Transformational' Results in Squamous Cell Lung Cancer An immuno-chemotherapy combination again moves the bar forward in a difficult-to-treat subset of squamous cell lung cancer patients.
  Medscape Medical News, October 2018
• WCLC 2018Dog Sniffs Out Lung Cancer, but Something’s Fishy A trained dog distinguished malignant from benign nodules from exhaled breath samples with great accuracy, but its trainer may be giving away the answers.
  Medscape Medical News, October 2018
• Pazopanib Shows Promise in Rare Cancer Syndrome Antiangiogenic agent could slow lesion growth in von Hippel-Lindau disease, sparing patients multiple surgical resections and deteriorating quality of life.
  Medscape Medical News, October 2018
• WCLC 2018After Decades, New Standard of Care in Small Cell Lung Cancer The first treatment advance in decades in small cell lung cancer couples immunotherapy with standard chemotherapy to move the bar.
  Medscape Medical News, September 2018
• Alert Dacomitinib (Vizimpro) Approved for EGFRm NSCLC Another targeted agent is now available for use in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) that harbors EGFR mutations.
  FDA Approvals, September 2018
• WCLC 2018Second Large Study Shows That Lung Cancer Screening Works NELSON shows that lung cancer screening reduces deaths in high-risk individuals, and also finds that repeat scans pose little burden on the healthcare system.
  Medscape Medical News, September 2018
• WCLC 2018Brigatinib: 'Very Promising' as First Line for ALK+ Lung Cancer Next-generation brigatinib trumps the first approved inhibitor, significantly prolonging disease progression or death in ALK-inhibitor-naive, advanced ALK+ lung cancer.
  Medscape Medical News, September 2018
• WCLC 2018Durvalumab New Standard in Stage III Unresectable Lung Cancer Now with data showing an overall survival advantage, the immunotherpy sets new standard of care in stage III unresectable lung cancer following concurrent chemotherapy and radiotherapy.
  Medscape Medical News, September 2018
• WCLC 2018Air Pollution Increases Lung Cancer Risk in Nonsmokers Women who have never smoked, especially Asian women, are highly susceptible to develop lung cancer if exposed to high levels of air pollution.
  Medscape Medical News, September 2018